The potential of PARP inhibitors in new cancer groups and in combination with other treatments

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Cutting-edge cancer care at the Miami Cancer Institute

Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL

Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma

CheckMate-142: Updated data from MSI high metastatic colon cancer patients